Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer

Scandinavian Journal of Immunology

Volumn 69, Issue 1, 2009, Pages 57-63

  Liu, W ^a   Wang, P ^b   Li, Z ^a   Xu, W ^a   Dai, L ^b   Wang, K ^b   Zhang, J ^b  

^a DALIAN MUNICIPAL CENTRAL HOSPITAL   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MYC PROTEIN; PROTEIN IMP1; PROTEIN KOC; PROTEIN P53; PROTEIN P62; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-MYB; PROTO-ONCOGENE PROTEINS C-MYC; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149089567     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02195.x     Document Type: Article

References (32)

1. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001 108 : 1411 5.
2. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994 180 : 1 4.
3. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998 187 : 1163 7.
4. Zhang JY, Chan EKL, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 1999 189 : 1101 10.
5. Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclinB1 in hepatocellular carcinoma. Hepatology 1997 25 : 75 80.
6. Kao H, Marto JA, Hoffmann TK et al. Identification of cyclinB1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001 194 : 1313 23.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993 366 : 704 7.
8. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982 30 : 403 8.
9. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000 60 : 1777 88.
10. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997 15 : 3363 7.
11. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003 12 : 136 43.
12. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002 97 : 72 81.
13. Li M, Gu J. Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol 2005 11 : 4685 8.
14. Maxwell P. Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker. Br J Biomed Sci 1999 56 : 209 14.
15. Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999 26 : 556 60.
16. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and fellow-up of patients with colorectal cancer. Cancer Invest 2005 23 : 338 51.
17. Muller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997 14 : 2729 33.
18. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999 19 : 1262 70.
19. Rubin RL. Enzyme-linked immunosorbent assays for antibodies to native DNA, histones, and (H2A-H2B)-DNA. In : Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. Washington, DC : American Society for Microbiology, 1997 : 935 41.
20. Chen WQ. Assessing the validity and reliability of screening test. In : Li LM, ed. Epidemiology. Beijing : Publishing company of the people' health, 2004 : 289 92.
21. Baker SJ, Curran T. Oncogenic transcription factor: FOS, JUN, MYC, MYB, and ETS. In : Peters G, Vorsden KH, eds. Oncogenes and Tumour Suppressors. Oxford : Oxford University Press, 1997 : 155 85.
22. Lu M, Nakamura RM, Dent ED et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol 2001 159 : 945 53.
23. Zhang JY, Chan EKL. Autoantibodies to IGF-II RNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma. Autoimmun Rev 2002 1 : 146 53.
24. Zhang JY, Chan EK, Peng XX et al. Autoimmune resppnses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 2001 100 : 149 56.
25. Liu WH, Li Z, Wang P et al. Evaluation of diagnostic value on lung cancer using a panel of multiple tumor-associated antigens. Chin J Health Lab Technol 2006 16 : 1412 4.
26. Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005 353 : 1224 35.
27. Koziol JA, Zhang JY, Casiano CA et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003 9 : 5120 6.
28. Lubin R, Zalcman G, Bouchet L et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995 1 : 701 2.
29. Zalcman G, Schlichtholz B, Tredaniel J et al. Monitoring of p53 autoantibodies in lung cancer during therapy. Relationship to response to treatment. Clin Cancer Res 1998 4 : 1359 66.
30. Scanlan MJ, Chen YT, Williamson B et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998 76 : 652 8.
31. Nam MJ, Madoz-Gurpide J, Wang H et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003 3 : 2108 15.
32. Chen Y, Lin P, Qiu S et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 2007 30 : 1137 44.